Physician profile
Sheelmohan S Sachdev
NPI 1699794727
$1,063.19
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $238.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $129.75 | 2019 | |
| Glaxosmithkline, LLC. | $125.00 | 2019 | |
| Novo Nordisk INC | $108.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $103.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $80.95 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $77.85 | 2019-2020 | |
| Microport Orthopedics INC | $71.41 | 2019 | |
| Pfizer INC. | $63.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.21 | 2019-2020 | |
| Lilly USA, LLC | $47.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.75 | 2019 | |
| Valeritas, INC. | $24.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.57 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.11 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2020 | |
| Allergan, INC. | $13.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheelmohan Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.